Member Info for chrishutch

Lovely to see big players taking positions

Fusion antibodies really has a lot of potential to grow and grow. They have been working towards this point for a long time and I believe that they are close to a real jump in revenues. The company haven’t been great at self promotion or getting the word out but that is all about to become irrelevant as fundamentals will now be in charge of a rerate.

Yes Abcam especially is a very good and current connection!

Could be very useful.

I think you maybe right. The optics certainly suggest someone wants a fair chunk of stock.

Nice to see people building positions here ahead of news, hopefully a handsome return

👀Fusion’s client base includes eight of the top 10 global pharmaceutical companies by revenue.

👀Big name Collaborations such as the National Cancer Institute (NCI)

👀Strategic Partnerships like the Future Medicines Institute (FMI) which give #FAB access to £5 million in cutting-edge equipment and 20 top-tier scientists through its partnership with Queen’s University Belfast strengthens its R&D capabilities without diluting shareholder equity.

👀 USA Patent application close to being granted.

👀Validation news on its way.

👀 Strong leadership team who are aligned with shareholders interests. Non execs taking shares in lieu of salary.

👀 Expert big name Scientific Advisory Panel.

👀World leaders in their field.

👀 In current discussions with potential licensing partners.

The appointment of Dr. Adrian Kinkaid as CEO in August 2022 has been a pivotal move. Kinkaid’s leadership has driven the integration of Fusion’s services into a streamlined, end-to-end offering, yielding “exceptionally good results” in trials with existing clients. The addition of world-renowned experts to the Scientific Advisory Panel, including Matthew Baker, Terry Rabbitts, and Charlotte Deane, further enhances Fusion’s credibility and innovation capacity.

You can’t underestimate a strong team to drive growth, the list of inventor names on US patent application, shows the level of skill runs all the way through the company.

I would add that potentially the patent and or the validation by the NCI should be a catalyst for a much higher news flow period.

I agree Sean. If granted, the U.S. patent for Fusion Antibodies’ OptiMAL® platform could significantly enhance the company’s competitive position, strengthen its IP portfolio, and support its growth in the U.S. biologics market. It would provide legal protection for its proprietary antibody library and design methods, potentially attracting more clients, enabling licensing opportunities, and boosting investor confidence.

Apologies for readability, on phone in sunshine.

The patent will certainly add to the credibility of the company and its value to prospective clients or those that would like to take fab over.

A while back we discussed end goals and whether fusion could be a prime candidate for take over or merger. The general consensus was that fab was and is, big pharma would be able to snap this up without breaking a sweat for many multiples of current share price.

We know from recent investor meet presentation and communications with the company that they have been in discussions with big commercial players with a view to licensing the products and services. The thought must have crossed their minds, especially given the improved merger and acquisition market, in the sector.

Someone raised why not just go to china and get services cheaper them? Which is a valid question.

My two cents on this is that fusion are world leaders with high profile names (not going to list them all) attached. And china sweat shop antibody firms aren’t. The obvious damage Covid did to chinas kerb appeal, there is the USA/china trade situation and of course the now the hopefully emerging patent protection for fusion antibodies.

When evaluating fab being pt protected in USA and UK is not just about an intraday share price move, it is a long term winner for the company , its credibility, its a stamp of trust, like being certified organic for a vegetable grow, it adds massive attraction

And Adrian ceo commented “ There are some exciting times ahead and it's great to have you all with us.”

Added

Oi cum guzzler, the personal attacks are not needed.

On the investor hub.

True mm, I am happy to float about at the minute. The company said we will update the market on Adrian’s sleeve news in due course, today.

Also, a few things in the pipeline news wise, some higher profile, and add commercial value. but I would rather they landed without the 20% range traders knowing ahead of time. And we both know they do t research haha

Nice to see a bit of blue!

Great, easy pickings for you.

I am buying a few more

I would like to think that with the sector finally coming to its senses after a very long period of pricing zero into everything . That many smaller companies will be able to flourish as sentiment returns. Our smaller clients, have struggled with valuations where listed or if not then getting vc backing. Which meant fusion had work on hold and a lack of new projects, this however is changing for the industry and fusion indirectly can hopefully profit from this. The diversification driven by fusion into multiple areas was a smart move, as it left the less dependant on one type of work.